Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + nab-paclitaxel
- Development stage
- Phase 2
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Cisplatin + nab-paclitaxel is a combination chemotherapy regimen used primarily in the treatment of various cancers, including metastatic breast cancer and head and neck squamous cell carcinoma. Cisplatin is a platinum-containing compound that forms DNA crosslinks, leading to apoptosis in rapidly dividing tumor cells. Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of paclitaxel, which inhibits microtubule disassembly during cell division, thereby blocking mitosis and inducing cancer cell death. The albumin-bound formulation (nab) allows for improved delivery and reduced hypersensitivity reactions compared to conventional solvent-based paclitaxel[1][2][4]. This combination has demonstrated enhanced efficacy compared to single-agent therapy or other combinations in certain settings, with manageable toxicity profiles[2][5].
- Brand names
- Abraxane + cisplatin
- Other names
- albumin-bound paclitaxelnab paclitaxelnanoparticle albumin-bound paclitaxel
02
Targets
DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on cisplatin + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + nab-paclitaxel.